Equities research analysts at HC Wainwright lowered their Q4 2025 earnings estimates for Neurocrine Biosciences in a report issued on Friday, February 21st. HC Wainwright analyst A. Fein now expects ...
Over the last 7 days, the United States market has dropped 2.2%, yet it remains up by 18% over the past year with earnings expected to grow by 14% per annum in the coming years. In this context, ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results